120 related articles for article (PubMed ID: 33648834)
1. A randomized trial to examine the impact of food on pharmacokinetics of 4-phenylbutyrate and change in amino acid availability after a single oral administration of sodium 4-phenylbutyrarte in healthy volunteers.
Osaka S; Nakano S; Mizuno T; Hiraoka Y; Minowa K; Hirai S; Mizutani A; Sabu Y; Miura Y; Shimizu T; Kusuhara H; Suzuki M; Hayashi H
Mol Genet Metab; 2021 Apr; 132(4):220-226. PubMed ID: 33648834
[TBL] [Abstract][Full Text] [Related]
2. Influence of food on pharmacokinetics and pharmacodynamics of 4-phenylbutyrate in patients with urea cycle disorders.
Nakajima Y; Osaka S; Mizuno T; Yokoi K; Nakano S; Hirai S; Hiraoka Y; Miura Y; Suzuki M; Kusuhara H; Hayashi H
Mol Genet Metab Rep; 2021 Dec; 29():100799. PubMed ID: 34522617
[TBL] [Abstract][Full Text] [Related]
3. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders.
Burrage LC; Jain M; Gandolfo L; Lee BH; ; Nagamani SC
Mol Genet Metab; 2014; 113(1-2):131-5. PubMed ID: 25042691
[TBL] [Abstract][Full Text] [Related]
4. Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis.
Nakano S; Osaka S; Sabu Y; Minowa K; Hirai S; Kondou H; Kimura T; Azuma Y; Watanabe S; Inui A; Bessho K; Nakamura H; Kusano H; Nakazawa A; Tanikawa K; Kage M; Shimizu T; Kusuhara H; Zen Y; Suzuki M; Hayashi H
Sci Rep; 2019 Nov; 9(1):17075. PubMed ID: 31745229
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial to study the comparative efficacy of phenylbutyrate and benzoate on nitrogen excretion and ureagenesis in healthy volunteers.
Nagamani SCS; Agarwal U; Tam A; Azamian M; McMeans A; Didelija IC; Mohammad MA; Marini JC
Genet Med; 2018 Jul; 20(7):708-716. PubMed ID: 29693650
[TBL] [Abstract][Full Text] [Related]
6. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.
Berry SA; Lichter-Konecki U; Diaz GA; McCandless SE; Rhead W; Smith W; Lemons C; Nagamani SC; Coakley DF; Mokhtarani M; Scharschmidt BF; Lee B
Mol Genet Metab; 2014 May; 112(1):17-24. PubMed ID: 24630270
[TBL] [Abstract][Full Text] [Related]
7. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
Longo N; Diaz GA; Lichter-Konecki U; Schulze A; Inbar-Feigenberg M; Conway RL; Bannick AA; McCandless SE; Zori R; Hainline B; Ah Mew N; Canavan C; Vescio T; Kok T; Porter MH; Berry SA
Mol Genet Metab; 2021 Jan; 132(1):19-26. PubMed ID: 33388234
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders.
Berry SA; Vockley J; Vinks AA; Dong M; Diaz GA; McCandless SE; Smith WE; Harding CO; Zori R; Ficicioglu C; Lichter-Konecki U; Perdok R; Robinson B; Holt RJ; Longo N
Mol Genet Metab; 2018 Nov; 125(3):251-257. PubMed ID: 30217721
[TBL] [Abstract][Full Text] [Related]
9. Phenylbutyrate improves nitrogen disposal via an alternative pathway without eliciting an increase in protein breakdown and catabolism in control and ornithine transcarbamylase-deficient patients.
Marini JC; Lanpher BC; Scaglia F; O'Brien WE; Sun Q; Garlick PJ; Jahoor F; Lee B
Am J Clin Nutr; 2011 Jun; 93(6):1248-54. PubMed ID: 21490144
[TBL] [Abstract][Full Text] [Related]
10. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
Smith W; Diaz GA; Lichter-Konecki U; Berry SA; Harding CO; McCandless SE; LeMons C; Mauney J; Dickinson K; Coakley DF; Moors T; Mokhtarani M; Scharschmidt BF; Lee B
J Pediatr; 2013 Jun; 162(6):1228-34, 1234.e1. PubMed ID: 23324524
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-Up on a Cohort Temporary Utilization Authorization (ATU) Survey of Patients Treated with Pheburane (Sodium Phenylbutyrate) Taste-Masked Granules.
Kibleur Y; Guffon N
Paediatr Drugs; 2016 Apr; 18(2):139-44. PubMed ID: 26747635
[TBL] [Abstract][Full Text] [Related]
12. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients.
Scaglia F; Carter S; O'Brien WE; Lee B
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S79-85. PubMed ID: 15050979
[TBL] [Abstract][Full Text] [Related]
13. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
Mokhtarani M; Diaz GA; Rhead W; Lichter-Konecki U; Bartley J; Feigenbaum A; Longo N; Berquist W; Berry SA; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Bart S; Kronn D; Zori R; Cederbaum S; Dorrani N; Merritt JL; Sreenath-Nagamani S; Summar M; Lemons C; Dickinson K; Coakley DF; Moors TL; Lee B; Scharschmidt BF
Mol Genet Metab; 2012 Nov; 107(3):308-14. PubMed ID: 22958974
[TBL] [Abstract][Full Text] [Related]
14. Results from a Nationwide Cohort Temporary Utilization Authorization (ATU) survey of patients in france treated with Pheburane(®) (Sodium Phenylbutyrate) taste-masked granules.
Kibleur Y; Dobbelaere D; Barth M; Brassier A; Guffon N
Paediatr Drugs; 2014 Oct; 16(5):407-15. PubMed ID: 24962711
[TBL] [Abstract][Full Text] [Related]
15. Taste-masked formulation of sodium phenylbutyrate (ACER-001) for the treatment of urea cycle disorders.
Cederbaum SD; Edwards J; Kellmeyer T; Peters Y; Steiner RD
Mol Genet Metab; 2023 Apr; 138(4):107558. PubMed ID: 37004302
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
Lee B; Rhead W; Diaz GA; Scharschmidt BF; Mian A; Shchelochkov O; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Gargosky S; Mokhtarani M; Berry SA
Mol Genet Metab; 2010 Jul; 100(3):221-8. PubMed ID: 20382058
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disorders.
Monteleone JP; Mokhtarani M; Diaz GA; Rhead W; Lichter-Konecki U; Berry SA; Lemons C; Dickinson K; Coakley D; Lee B; Scharschmidt BF
J Clin Pharmacol; 2013 Jul; 53(7):699-710. PubMed ID: 23775211
[TBL] [Abstract][Full Text] [Related]
18. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate.
Diaz GA; Krivitzky LS; Mokhtarani M; Rhead W; Bartley J; Feigenbaum A; Longo N; Berquist W; Berry SA; Gallagher R; Lichter-Konecki U; Bartholomew D; Harding CO; Cederbaum S; McCandless SE; Smith W; Vockley G; Bart SA; Korson MS; Kronn D; Zori R; Merritt JL; C S Nagamani S; Mauney J; Lemons C; Dickinson K; Moors TL; Coakley DF; Scharschmidt BF; Lee B
Hepatology; 2013 Jun; 57(6):2171-9. PubMed ID: 22961727
[TBL] [Abstract][Full Text] [Related]
19. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
Lichter-Konecki U; Diaz GA; Merritt JL; Feigenbaum A; Jomphe C; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt B; Rhead W
Mol Genet Metab; 2011 Aug; 103(4):323-9. PubMed ID: 21612962
[TBL] [Abstract][Full Text] [Related]
20. Developing a new formulation of sodium phenylbutyrate.
Guffon N; Kibleur Y; Copalu W; Tissen C; Breitkreutz J
Arch Dis Child; 2012 Dec; 97(12):1081-5. PubMed ID: 22941860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
